Kura Oncology (NASDAQ:KURA) Rating Increased to Hold at StockNews.com

StockNews.com upgraded shares of Kura Oncology (NASDAQ:KURA) from a sell rating to a hold rating in a research note published on Thursday morning.

A number of other equities analysts have also recently issued reports on KURA. Jefferies Financial Group cut their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating on the stock in a report on Thursday, November 21st. BTIG Research lowered shares of Kura Oncology from a “buy” rating to a “neutral” rating in a research note on Thursday, February 6th. Bank of America decreased their target price on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. Scotiabank lowered their target price on shares of Kura Oncology from $18.00 to $10.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $40.00 price target on shares of Kura Oncology in a research note on Thursday. Four investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average price target of $27.13.

Kura Oncology Stock Down 1.5 %

Shares of NASDAQ KURA opened at $7.65 on Thursday. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $594.89 million, a PE ratio of -3.24 and a beta of 0.78. The company’s fifty day simple moving average is $8.19 and its 200 day simple moving average is $13.92. Kura Oncology has a 12-month low of $6.98 and a 12-month high of $24.17.

Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, February 26th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.65) by $0.43. The firm had revenue of $53.88 million during the quarter, compared to analyst estimates of $57.96 million. As a group, sell-side analysts forecast that Kura Oncology will post -2.44 earnings per share for the current fiscal year.

Insider Activity

In other news, SVP Thomas James Doyle sold 4,949 shares of the firm’s stock in a transaction on Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $38,948.63. Following the completion of the sale, the senior vice president now directly owns 88,193 shares of the company’s stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mollie Leoni sold 4,963 shares of the business’s stock in a transaction dated Tuesday, January 28th. The stock was sold at an average price of $7.87, for a total transaction of $39,058.81. Following the completion of the transaction, the insider now directly owns 88,253 shares in the company, valued at $694,551.11. This trade represents a 5.32 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,729 shares of company stock valued at $92,307 over the last three months. Corporate insiders own 5.50% of the company’s stock.

Institutional Trading of Kura Oncology

Large investors have recently added to or reduced their stakes in the stock. Barclays PLC grew its position in shares of Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company’s stock valued at $3,234,000 after acquiring an additional 84,563 shares during the period. SG Americas Securities LLC bought a new position in Kura Oncology during the fourth quarter valued at $436,000. Moody Aldrich Partners LLC grew its holdings in Kura Oncology by 42.3% during the fourth quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company’s stock valued at $1,251,000 after purchasing an additional 42,712 shares during the period. Harbor Capital Advisors Inc. increased its position in Kura Oncology by 4.4% in the fourth quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company’s stock worth $430,000 after buying an additional 2,076 shares during the last quarter. Finally, Jennison Associates LLC bought a new stake in shares of Kura Oncology in the fourth quarter valued at $623,000.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.